Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling
Xiwu Chen, … , Roy Zent, Ambra Pozzi
Xiwu Chen, … , Roy Zent, Ambra Pozzi
Published July 1, 2014
Citation Information: J Clin Invest. 2014;124(8):3295-3310. https://doi.org/10.1172/JCI71668.
View: Text | PDF
Research Article Nephrology

Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling

  • Text
  • PDF
Abstract

Tubulointerstitial fibrosis underlies all forms of end-stage kidney disease. TGF-β mediates both the development and the progression of kidney fibrosis through binding and activation of the serine/threonine kinase type II TGF-β receptor (TβRII), which in turn promotes a TβRI-mediated SMAD-dependent fibrotic signaling cascade. Autophosphorylation of serine residues within TβRII is considered the principal regulatory mechanism of TβRII-induced signaling; however, there are 5 tyrosine residues within the cytoplasmic tail that could potentially mediate TβRII-dependent SMAD activation. Here, we determined that phosphorylation of tyrosines within the TβRII tail was essential for SMAD-dependent fibrotic signaling within cells of the kidney collecting duct. Conversely, the T cell protein tyrosine phosphatase (TCPTP) dephosphorylated TβRII tail tyrosine residues, resulting in inhibition of TβR-dependent fibrotic signaling. The collagen-binding receptor integrin α1β1 was required for recruitment of TCPTP to the TβRII tail, as mice lacking this integrin exhibited impaired TCPTP-mediated tyrosine dephosphorylation of TβRII that led to severe fibrosis in a unilateral ureteral obstruction model of renal fibrosis. Together, these findings uncover a crosstalk between integrin α1β1 and TβRII that is essential for TβRII-mediated SMAD activation and fibrotic signaling pathways.

Authors

Xiwu Chen, Hongtao Wang, Hong-Jun Liao, Wen Hu, Leslie Gewin, Glenda Mernaugh, Sheng Zhang, Zhong-Yin Zhang, Lorenzo Vega-Montoto, Roberto M. Vanacore, Reinhard Fässler, Roy Zent, Ambra Pozzi

×

Figure 7

Spermidine ameliorates TβR-activated signaling in α1KO CD cells and mice.

Options: View larger image (or click on image) Download as PowerPoint
Spermidine ameliorates TβR-activated signaling in α1KO CD cells and mice...
(A) Morphology of α1KO CD cells cultured on plastic in 0.2% serum with or without spermidine (SP) for 4 days (B) Serum-starved α1KO CD cells were treated with spermidine for 24 hours at the concentrations indicated. Cell lysates (20 μg/lane) were analyzed by Western blot for levels of pSMAD3, SMAD3, and collagen I. (C) Cell lysates (0.5 mg) from serum-starved WT and α1KO CD cells, treated or not for 24 hours with 2.5 μM spermidine, were incubated with 4G10 (10 μg) or mouse IgG isotype control antibody (10 μg). Immunoprecipitation products were then analyzed as in Figure 6A. Lanes were run on the same gel but were noncontiguous (black line). (D) H&E and Trichrome staining of kidneys from α1KO mice untreated or treated with spermidine (30 μM via gavage) at 7 days post-UUO, showing less injury and collagen deposition (blue staining) in the spermidine-treated group. (E and G) Kidney lysates (10 μg/lane) from injured α1KO (n = 4) and spermidine-treated α1KO (n = 3) mice were analyzed by Western blot for levels of collagen I, collagen IV, pSMAD3, and SMAD3. (F and H) Collagen I, collagen IV, β-actin, pSMAD3, and SMAD3 bands were quantified by densitometry analysis; signal is expressed as the collagen I/β-actin or pSMAD/SMAD ratio. Values are mean ± SEM of the indicated n. Scale bars: 20 μm (A); 100 μm (D).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts